{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T22:56:56Z","timestamp":1783465016685,"version":"3.55.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T00:00:00Z","timestamp":1651795200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Cl\u00ednica Espa\u00f1ola (English Edition)"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.rceng.2021.12.006","type":"journal-article","created":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T16:12:23Z","timestamp":1650730343000},"page":"359-369","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Vericiguat in heart failure: From scientific evidence to clinical practice"],"prefix":"10.1016","volume":"222","author":[{"given":"J.R.","family":"Gonz\u00e1lez-Juanatey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Anguita-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bayes-Gen\u00eds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Com\u00edn-Colet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Garc\u00eda-Quintana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Recio-Mayoral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Zamorano-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Cepeda-Rodrigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Manzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rceng.2021.12.006_bib0005","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/ejhf.1858","article-title":"Epidemiology of heart failure","volume":"22","author":"Groenewegen","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.rceng.2021.12.006_bib0010","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12872-018-0815-3","article-title":"Cost-of-illness studies in heart failure: a systematic review 2004\u20132016","volume":"18","author":"Lesyuk","year":"2018","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.rceng.2021.12.006_bib0015","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","volume":"390","author":"GBD","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.rceng.2021.12.006_bib0020","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.recesp.2020.03.020","article-title":"Insuficiencia cardiaca de novo tras un s\u00edndrome coronario agudo en pacientes sin insuficiencia cardiaca ni disfunci\u00f3n ventricular izquierda","volume":"74","author":"Cordero","year":"2021","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.rceng.2021.12.006_bib0025","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.recesp.2020.03.022","article-title":"Insuficiencia cardiaca y medicina basada en la evidencia: no todo est\u00e1 en las gu\u00edas","volume":"73","author":"Anguita","year":"2020","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.rceng.2021.12.006_bib0030","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","article-title":"American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2020 update: A report from the American Heart Association","volume":"141","author":"Virani","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.rceng.2021.12.006_bib0035","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/ejhf.471","article-title":"ARNO Observatory. The real-world evidence of heart failure: findings from 41\u202f413 patients of the ARNO database","volume":"18","author":"Maggioni","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.rceng.2021.12.006_bib0040","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s11897-019-00442-1","article-title":"Patient-associated predictors of 15- and 30-day readmission after hospitalization for acute heart failure","volume":"16","author":"Delgado","year":"2019","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.rceng.2021.12.006_bib0045","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ijcard.2017.06.106","article-title":"Trends in comorbidity in patients hospitalised for cardiovascular disease","volume":"248","author":"Buddeke","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.rceng.2021.12.006_bib0050","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.amjcard.2015.07.018","article-title":"Comparison of risk of re-hospitalization, all-cause mortality, and medical care resource utilization in patients with heart failure and preserved versus reduced ejection fraction","volume":"116","author":"Nichols","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.rceng.2021.12.006_bib0055","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ehf2.12005","article-title":"Heart failure: preventing disease and death worldwide","volume":"1","author":"Ponikowski","year":"2014","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.rceng.2021.12.006_bib0060","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s10741-017-9661-0","article-title":"Systematic review of economic burden of heart failure","volume":"23","author":"Shafie","year":"2018","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.rceng.2021.12.006_bib0065","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejim.2019.02.019","article-title":"Significant and constant increase in hospitalization due to heart failure in Spain over 15 year period","volume":"64","author":"M\u00e9ndez-Bail\u00f3n","year":"2019","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.rceng.2021.12.006_bib0070","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1186\/s12913-020-05828-9","article-title":"Costs and healthcare utilisation of patients with heart failure in Spain","volume":"20","author":"Escobar","year":"2020","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.rceng.2021.12.006_bib0075","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1001\/jamacardio.2017.5250","article-title":"Outpatient worsening heart failure as a target for therapy: a review","volume":"3","author":"Greene","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.rceng.2021.12.006_bib0080","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.jacc.2018.11.049","article-title":"Clinical course of patients with worsening heart failure with reduced ejection fraction","volume":"73","author":"Butler","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rceng.2021.12.006_bib0085","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jacc.2012.09.038","article-title":"Rehospitalization for heart failure: problems and perspectives","volume":"61","author":"Gheorghiade","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rceng.2021.12.006_bib0090","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ahj.2007.01.041","article-title":"Repeated hospitalizations predict mortality in the community population with heart failure","volume":"154","author":"Setoguchi","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.rceng.2021.12.006_bib0095","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.medcli.2019.03.020","article-title":"Short term prognosis of heart failure after first hospital admission","volume":"154","author":"Masip","year":"2020","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.rceng.2021.12.006_bib0100","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.recesp.2020.09.014","article-title":"Epidemiolog\u00eda y tratamiento de la insuficiencia cardiaca en Espa\u00f1a: estudio PATHWAYS-HF","volume":"75","author":"Sicras-Mainar","year":"2022","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10.1016\/j.rceng.2021.12.006_bib0105","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41598-020-79926-3","article-title":"Mortality trends in an ambulatory multidisciplinary heart failure unit from 2001 to 2018","volume":"11","author":"Spitaleri","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.rceng.2021.12.006_bib0110","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1111\/imj.14289","article-title":"Discharge treatment with angiotensin-converting enzyme inhibitor\/angiotensin receptor blocker after a heart failure hospitalisation is associated with a better prognosis irrespective of left ventricular ejection fraction","volume":"49","year":"2019","journal-title":"Intern Med J"},{"key":"10.1016\/j.rceng.2021.12.006_bib0115","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.jacc.2009.05.015","article-title":"The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications","volume":"54","author":"Triposkiadis","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rceng.2021.12.006_bib0120","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.rceng.2021.12.006_bib0125","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jacc.2020.11.022","volume":"77","author":"Maddox","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rceng.2021.12.006_bib0130","first-page":"531","article-title":"CCS\/CHFS heart failure guidelines update: defining a new pharmacologic standard of care for heart failure with reduced ejection fraction","volume":"37","author":"McDonald","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.rceng.2021.12.006_bib0135","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12947-019-0177-8","article-title":"Effect of sodium glucose cotransporter 2 inhibitors on cardiac function and cardiovascular outcome: a systematic review","volume":"17","author":"Matsumura","year":"2019","journal-title":"Cardiovasc Ultrasound"},{"key":"10.1016\/j.rceng.2021.12.006_bib0140","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jchf.2017.08.013","article-title":"A multicenter, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral soluble guanylate cyclase stimulator: The VICTORIA trial","volume":"6","author":"Armstrong","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.rceng.2021.12.006_bib0145","doi-asserted-by":"crossref","first-page":"60","DOI":"10.14740\/cr1221","article-title":"A review of the proposed mechanistic actions of sodium glucose cotransporter-2 inhibitors in the treatment of heart failure","volume":"12","author":"Nightingale","year":"2021","journal-title":"Cardiol Res"},{"key":"10.1016\/j.rceng.2021.12.006_bib0150","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","article-title":"Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials","volume":"396","author":"Vaduganathan","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.rceng.2021.12.006_bib0155","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.recesp.2019.09.012","article-title":"Cambio en la causa de muerte e influencia de la mejora terap\u00e9utica con el tiempo en pacientes con insuficiencia cardiaca y fracci\u00f3n de eyecci\u00f3n reducida","volume":"73","author":"Fern\u00e1ndez-V\u00e1zquez","year":"2020","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.rceng.2021.12.006_bib0160","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/ejhf.1645","article-title":"Sex- and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry","volume":"22","author":"Lain\u0161\u010dak","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.rceng.2021.12.006_bib0165","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.rceng.2021.12.006_bib0170","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jacc.2020.05.037","article-title":"2020 Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"76","author":"Das","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rceng.2021.12.006_bib0175","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1161\/CIRCULATIONAHA.120.052926","article-title":"How should we sequence the treatments for heart failure and a reduced ejection fraction? A redefinition of evidence-based medicine","volume":"143","author":"McMurray","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.rceng.2021.12.006_bib0180","unstructured":"Ficha t\u00e9cnica de vericiguat. Primera publicaci\u00f3n 27 Jul 2021 [Accessed Nov 2021]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/verquvo-epar-public-assessment-report_en.pdfhttps:\/\/ec.europa.eu\/health\/documents\/community-register\/2021\/20210716152073\/anx_152073_es.pdf."},{"key":"10.1016\/j.rceng.2021.12.006_bib0185","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1002\/ejhf.2009","article-title":"Ten lessons from the EMPEROR-reduced trial","volume":"22","author":"Butler","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.rceng.2021.12.006_bib0190","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jchf.2020.08.008","article-title":"N-Terminal Pro-B-Type natriuretic peptide and clinical outcomes: vericiguat heart failure with reduced ejection fraction study","volume":"8","author":"Ezekowitz","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.rceng.2021.12.006_bib0195","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10741-012-9323-1","article-title":"Academic Research Team in Heart Failure (ART-HF). Soluble guanylate cyclase: a potential therapeutic target for heart failure","volume":"18","author":"Gheorghiade","year":"2013","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.rceng.2021.12.006_bib0200","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/164_2018_197","article-title":"Soluble guanylate cyclase stimulators and activators","volume":"264","author":"Sandner","year":"2021","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.rceng.2021.12.006_bib0205","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1515\/hsz-2018-0155","article-title":"From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators","volume":"399","author":"Sandner","year":"2018","journal-title":"Biol Chem"},{"key":"10.1016\/j.rceng.2021.12.006_bib0210","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/13543776.2021.1866538","article-title":"Soluble guanylate cyclase stimulators and their potential use: a patent review","volume":"31","author":"Sandner","year":"2021","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.rceng.2021.12.006_bib0215","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/164_2016_100","article-title":"Novel sGC stimulators and sGC activators for the treatment of heart failure","volume":"243","author":"Breitenstein","year":"2017","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.rceng.2021.12.006_bib0220","doi-asserted-by":"crossref","first-page":"5146","DOI":"10.1021\/acs.jmedchem.7b00449","article-title":"Discovery of the soluble guanylate cyclase stimulator vericiguat (BAY 1021189) for the treatment of chronic heart failure","volume":"60","author":"Follmann","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.rceng.2021.12.006_bib0225","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/ejhf.1787","article-title":"Evaluation of high-sensitivity C-reactive protein and uric acid in vericiguat-treated patients with heart failure with reduced ejection fraction","volume":"22","author":"Kramer","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.rceng.2021.12.006_bib0230","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s40262-020-00895-x","article-title":"Metabolism and pharmacokinetic drug-drug interaction profile of vericiguat, a soluble guanylate cyclase stimulator: results from preclinical and phase i healthy volunteer studies","volume":"59","author":"Boettcher","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.rceng.2021.12.006_bib0235","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s40262-020-00935-6","article-title":"Pharmacodynamic and pharmacokinetic interaction profile of vericiguat: results from three randomized phase i studies in healthy volunteers","volume":"60","author":"Boettcher","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.rceng.2021.12.006_bib0240","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00228-020-03023-7","article-title":"Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects","volume":"77","author":"Boettcher","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.rceng.2021.12.006_bib0245","first-page":"1","article-title":"Vericiguat for the treatment of heart failure: mechanism of action and pharmacological properties compared with other emerging therapeutic options","author":"Hulot","year":"2021","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.rceng.2021.12.006_bib0250","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s40262-021-01024-y","article-title":"Population pharmacokinetics and pharmacodynamics of vericiguat in patients with heart failure and reduced ejection fraction","volume":"60","author":"Ruehs","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.rceng.2021.12.006_bib0255","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/ejhf.135","article-title":"SOCRATES Investigators and Coordinators. Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES)","volume":"16","author":"Pieske","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.rceng.2021.12.006_bib0260","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.2015.15734","volume":"314","author":"Gheorghiade","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.rceng.2021.12.006_bib0265","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/eurheartj\/ehw593","article-title":"Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study","volume":"38","author":"Pieske","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.rceng.2021.12.006_bib0270","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/ejhf.800","article-title":"Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study","volume":"19","author":"Filippatos","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.rceng.2021.12.006_bib0275","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"VICTORIA Study Group. Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rceng.2021.12.006_bib0280","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/ejhf.2221","article-title":"VICTORIA Study Group. Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial","volume":"23","author":"Voors","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.rceng.2021.12.006_bib0285","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1002\/ejhf.1664","article-title":"VICTORIA Study Group. Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial","volume":"21","author":"Pieske","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.rceng.2021.12.006_bib0290","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1001\/jamacardio.2020.6455","article-title":"VICTORIA Study Group. Clinical outcomes and response to vericiguat according to index heart failure event: insights from the VICTORIA trial","volume":"6","author":"Lam","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.rceng.2021.12.006_bib0295","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.005998","article-title":"Rationale and design of the VITALITY-HFpEF trial","volume":"12","author":"Butler","year":"2019","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.rceng.2021.12.006_bib0300","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1001\/jama.2020.15922","article-title":"VITALITY-HFpEF Study Group. Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: The VITALITY-HFpEF randomized clinical trial","volume":"324","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.rceng.2021.12.006_bib0305","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s10557-020-07099-2","article-title":"Relative efficacy of sacubitril-valsartan, vericiguat, and SGLT2 inhibitors in heart failure with reduced ejection fraction: a systematic review and network meta-analysis","volume":"35","author":"Aimo","year":"2020","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.rceng.2021.12.006_bib0310","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1161\/CIRCULATIONAHA.120.047086","article-title":"Comparing the benefit of novel therapies across clinical trials: insights from the VICTORIA Trial","volume":"142","author":"Butler","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.rceng.2021.12.006_bib0315","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rceng.2021.12.006_bib0320","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rceng.2021.12.006_bib0325","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"B","key":"10.1016\/j.rceng.2021.12.006_bib0330","first-page":"1","article-title":"Consenso de expertos sobre la insuficiencia cardiaca con fracci\u00f3n de eyecci\u00f3n reducida: m\u00e1s all\u00e1 de las gu\u00edas","volume":"20","author":"Anguita","year":"2020","journal-title":"Rev Esp Cardiol Supl"},{"key":"10.1016\/j.rceng.2021.12.006_bib0335","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/ejhf.2206","article-title":"Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology","volume":"23","author":"Rosano","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.rceng.2021.12.006_bib0340","first-page":"488","article-title":"Efficacy and safety of soluble guanylate cyclase stimulators in patients with heart failure: a systematic review and meta-analysis","volume":"76","author":"Li","year":"2021","journal-title":"Pharmazie"},{"key":"10.1016\/j.rceng.2021.12.006_bib0345","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.recesp.2021.06.011","article-title":"Consulta electr\u00f3nica (e-consulta) para pacientes con insuficiencia card\u00edaca. Resultados a largo plazo","volume":"75","author":"Cinza","year":"2022","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.rceng.2021.12.006_bib0350","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1007\/s12325-021-01681-2","article-title":"Budget impact analysis of vericiguat for the treatment of chronic heart failure with reduced ejection fraction following a worsening event","volume":"38","author":"Alsumali","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.rceng.2021.12.006_bib0355","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1378\/chest.14-0106","article-title":"Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study","volume":"146","author":"Bonderman","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.rceng.2021.12.006_bib0360","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1001\/jama.2020.16641","article-title":"Effect of praliciguat on peak rate of oxygen consumption in patients with heart failure with preserved ejection fraction: the CAPACITY HFpEF randomized clinical trial","volume":"324","author":"Udelson","year":"2020","journal-title":"JAMA"}],"container-title":["Revista Cl\u00ednica Espa\u00f1ola (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2254887422000285?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2254887422000285?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T08:49:17Z","timestamp":1762418957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2254887422000285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":72,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S2254887422000285"],"URL":"https:\/\/doi.org\/10.1016\/j.rceng.2021.12.006","relation":{},"ISSN":["2254-8874"],"issn-type":[{"value":"2254-8874","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vericiguat in heart failure: From scientific evidence to clinical practice","name":"articletitle","label":"Article Title"},{"value":"Revista Cl\u00ednica Espa\u00f1ola (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rceng.2021.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.rce.2021.12.005","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}